ID: ALA213743

Max Phase: Preclinical

Molecular Formula: C20H22N4S

Molecular Weight: 350.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1CCN(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)CC1

Standard InChI:  InChI=1S/C20H22N4S/c1-23-5-7-24(8-6-23)12-14-2-3-15-11-18-19(16-4-9-25-13-16)21-22-20(18)17(15)10-14/h2-4,9-10,13H,5-8,11-12H2,1H3,(H,21,22)

Standard InChI Key:  OLLCPXMBOYVHAF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 350.49

Molecular Weight (Monoisotopic): 350.1565

AlogP: 3.46

#Rotatable Bonds: 3

Polar Surface Area: 35.16

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.80

CX Basic pKa: 7.88

CX LogP: 3.21

CX LogD: 2.89

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.61

Np Likeness Score: -1.62

References

1. Dinges J, Akritopoulou-Zanze I, Arnold LD, Barlozzari T, Bousquet PF, Cunha GA, Ericsson AM, Iwasaki N, Michaelides MR, Ogawa N, Phelan KM, Rafferty P, Sowin TJ, Stewart KD, Tokuyama R, Xia Z, Zhang HQ..  (2006)  Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors.,  16  (16): [PMID:16750628] [10.1016/j.bmcl.2006.05.052]

2. Dinges J, Ashworth KL, Akritopoulou-Zanze I, Arnold LD, Baumeister SA, Bousquet PF, Cunha GA, Davidsen SK, Djuric SW, Gracias VJ, Michaelides MR, Rafferty P, Sowin TJ, Stewart KD, Xia Z, Zhang HQ..  (2006)  1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.,  16  (16): [PMID:16759855] [10.1016/j.bmcl.2006.05.066]

Source

Source(1):

• Scientific Literature